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High-dose chemotherapy and autologous bone marrow transplant in
relapsed Hodgkin's disease - a pragmatic prognostic index
MER O'Brien, S Milan, D Cunningham, AL Jones, M Nicolson, P Selby, T Hickish, M Hill,
ME Gore and C Viner
Cancer Research Campaign, Section ofMedicine and Lymphoma Unit, The Institute ofCancer Research and The Royal Marsden
Hospital, Sutton, Surrey, UK.
Summary High-dose chemotherapy with autologous bone marrow transplantation is used in the treatment of
relapsed or high-risk Hodgkin's disease. As prospective randomised studies have proved difficult to accrue to,
current recommendations are based on the reports of large series of prospectively collected data. We have
looked at the outcome of 89 patients treated in this way at a single institution and have developed an index to
predict outcome. Of 89 patients, with a median age of 29 years (range 15-51 years), eight patients were in first
complete remission/partial remission (CR/PR), 17 in second or later CR, 37 were responding relapses, 13
resistant relapses, 11 primary refractory and three untested relapses. Combinations of melphalan, BCNU and
etoposide were given in all cases except in ten patients who received melphalan alone. The median follow-up
was 43 months (range 6-77 months). A total of24 patients were in CR at the time ofautologous bone marrow
transplantation (ABMT), 33 achieved CR with ABMT, 16 PR, to give a response rate to ABMT of 49/
65=74% (95% CI 60-83%) with a CR rate of 51% (CI 36-62%). In a Cox's multivariate analysis the most
important factors in predicting outcome after ABMT were response to treatment before entry, number of
previous treatments and previous chemosensitivity. Using these factors we devised a prognostic index which
reliably selects a group of patients (65%) with at least a 70% chance of being progression free from 1 year
onwards. Patients who have never achieved a CR and have received three or more chemotherapy regimens do
not benefit from high-dose chemotherapy as used in this study.
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The mortality rate of patients receiving high-dose chemother-
apy with haematological support in the form of autologous
bone marrow transplantation (ABMT) has improved with
better patient selection, supportive medicine and the use of
peripheral blood stem cells and growth factors (Peters, 1993).
This procedure remains unproven in Hodgkin's disease (HD)
and at present decisions are based on the results reported in
one randomised trial and other retrospective series ofpatients
treated at different stages of HD when drug resistance is
either present or beginning to appear.
From the observation that patients with relapsed disease
when treated with conventional chemotherapy have a
progression-free survival (PFS) of around 30% and a
median survival of 12 months, it has become accepted that
fit patients with HD who have a first remission of < 12
months' duration, those who fail to achieve a complete
remission (CR) with satisfactory induction therapy including
an anthracycline, or those patients who are in second or
subsequent relapse, or high-risk patients in first relapse,
should be treated in this way (Goldstone and McMillan,
1993; Longo et al., 1992).
Lohri et al. (1991) described a group of 80 patients after
first relapse HD treated by four different treatment regimens
including one group of 16 patients who received high-dose
chemotherapy with ABMT. Freedom from second relapse
was the end point and was similar in all groups. More
recently the Vancouver group have reported their experience
with high-dose treatment in a group of HD patients after first
relapse from initial complete remission and compared the
outcome with that in patients treated with conventional
chemotherapy (Reece et al., 1994). The authors report a 64%
PFS for the group of 58 patients which is better than results
with conventional chemotherapy, e.g. the Milan group
reported a PFS of 46% in patients with initial remissions
of more than a year (Bonfante et al., 1993).
There is one randomised trial comparing high-dose
chemotherapy [BCNU, etoposide, cytarabine and melphalan
(BEAM)] with ABMT with a less intensive regimen
(miniBEAM) in patients with active HD who had failed
conventional chemotherapy. The numbers were small but did
show a significant event-free survival advantage (53% vs
10%) at a median follow-up of 34 months (P=0.025) in
favour of BEAM plus ABMT. There was no difference in
overall survival (Linch et al., 1993). The trial demonstrates
the difficulty in recruiting to a trial in which one of the
treatment modalities, although unproven, is seen to be the
best chance of long-term survival. A few years into this
randomised study, patients were refusing to be randomised
and requested high-dose treatment.
We report our experience at a single centre treating
relapsed or non-responding HD, the most common category
of patients seen being the sensitive relapses with a varying
number in each other subgroup. With long follow-up we
report both long- and short-term toxicity, response rates and
prognostic factors to help predict which patients will have a
long PFS
Patients and methods
A group of 89 unselected patients treated at a single
institution with high-dose chemotherapy and bone marrow
transplant between 1 October 1985 and 1 March 1992 is
presented.
Patients and previous treatment
Characteristics at diagnosis and at the time of high-dose
chemotherapy and ABMT are shown in Table I. Data on
lactate dehydrogenase (LDH) levels were not available in a
large enough percentage of patients to be included in the
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analysis. The median follow-up of survivors was 43 months
(range 6-77 months). At the time of ABMT, the median age
was 29 years (range 15-51 years). The median time from
diagnosis until ABMT was 2.5 years (range 4.3 months-14
years) There were 58 patients who were treated at hospitals
and were referred in remission for high-dose consolidation
therapy. The first treatment regimen given at the onset of
disease was Ch1VPP, 37 patients; MOPP, four patients;
LOPP, nine patients; VEEP, eight patients; other anthracy-
cline combination, 26 patients, and radiotherapy alone, five
patients. Before high-dose therapy all patients had received
previous chemotherapy with a median of two regimens per
patient. There were 51/89 patients who had received
radiotherapy with 37/51 receiving radiotherapy to the
mediastinum. Bleomycin had been given to 39/89 patients
during previous chemotherapy.
Seven patients in first CR were all patients with advanced
stage disease (IIIA, two patients; IIIB, two patients; and IVB,
three patients) who had required at least two treatment
regimens to obtain their first CR. Thus, 24 patients were in
complete remission (CR) at the time of high-dose treatment.
There were 41 patients in partial remission (PR) after the
most recent chemotherapy, i.e. before high-dose treatment, 12
had no response (NR), nine had progressive disease (PD) and
three were untested. It was not possible, retrospectively, to
define patients who had a CR unconfirmed (CRu), as this is a
recently introduced term of response. According to the
known categories described by Philip et al. (1987) in relapsed
non-Hodgkin's lymphoma at the time of ABMT, eight
patients were in first CR/PR, 17 in second or later CR, 24
were responding relapses, 13 resistant relapses, 11 primary
refractory and three untested relapses (Table II).
Conditioning regimens
Melphalan as a single agent (180-220 mg m-2) was used in
the first phase of the study in ten patients. BCNU (300-
600 mg m-2) was then added to the melphalan (80-
140 mg m-2) and given to 11 patients and then etoposide
Table I Patient characteristics (n = 89)
Gender
Male
Female
Stage at diagnosis
I
II
III
IV
Symptoms at diagnosis
A
B
At ABMT
Age (years)
Median
Range
Symptoms
A
B
Nodal disease
Yes
No
Extranodal disease
Yes
No
CR ever
Yes
No
Number of previous chemotheropy regimens
1
2
3
4
S
54
35
2
24
29
34
35
54
29
15-51
71
18
59
30
31
58
65
24
3
44
28
8
6
(300 mg m-2) was added to the combination (MBE) and
given to 61 patients. Melphalan (140 mg m-2) and etoposide
(1200 mg m-2) without BCNU was given to seven patients
who had poor pulmonary function tests. Melphalan was
given with intravenous hydration and forced diuresis and
when used as a single agent fresh bone marrow was returned
6 h after infusion of the drug. Combinations of drug were
given as per standard protocols with cryopreserved bone
marrow (Harding et al., 1992).
Statistical methods
The unit policy was to treat to maximum response as defined
by UICC criteria (Miller et al., 1981). Kaplan-Meier
actuarial survival and progression-free survival were calcu-
lated for all patients. Progression rather than survival was
chosen for the Cox analysis because there were a large
number of late deaths owing to factors other than HD in this
group of patients. The factors causing these deaths are not
the same as the factors influencing death from HD, and as
some patients who died did not have relapsed HD it was
decided that the strongest model for predicting the effect of
ABMT on the disease process would be obtained by
examining the factors influencing progression.
The three untested relapses were not included in the Cox's
analysis and the analysis was repeated with and without the
patients in first CR (n =7) and first PR (n = 1). Neither of
these omissions significantly changed any results.
An early treatment-related death was defined as a death
within 2 months of ABMT. After the initial 2 month
transplant period subsequent events have been termed late
toxicities.
Results
Response rate
A total of 24 patients were in CR at the time of ABMT, 33
achieved CR with ABMT, 16 PR, 16 NR and three early
treatment deaths (two of these patients were in CR before
ABMT) to give a response rate to ABMT of 49/65=74%
(95% CI 60-83%) with a CR rate of 33/65=51% (CI 36-
62%). A total of 57/89=64% of patients were therefore in
CR at the end of the procedure.
Primary refractory disease and resistant relapses (Table II)
In all, 6/11 patients had a complete remission. Two of these
patients developed pneumonitis and died without relapsed
disease, both had a BCNU dose of 600 mg m-2, one had
mediastinal radiotherapy and both had received two previous
chemotherapy regimens. One patient in CR died of infection
having had four previous treatment regimens, two patients
have relapsed and only one remains in remission 56 months
later.
In the group of resistant relapses, no CR were documented
and 6/13 patients achieved a PR, 4/6 have died of progressive
disease, one is alive at 20 months in continued PR and one
Table II Outcome by status at ABMT
Outcome after ABMT
Status at ABMT Already CR CR PR NR Total
First CR/PR 7 8* 0 0 8
Subsequent CR 17 17* 0 0 17
Responding relapse 0 24 5 8 37
Resistant relapse 0 0 6 7 13
Primary refractory 0 6 4* 1 11
Untested relapse 0 2 1 0 3
*Patient within group who had treatment-related death, i.e. within 2
months oftreatment.High-dose chemotherapy in Hodgkin's disease
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went from a PR to a CR with mantle radiotherapy and is
alive and well 43 months on. A patient with NR is still alive
at 16 months.
Deaths and early/late toxicities (Table III)
Three toxic deaths occurred early (within 2 months of the
transplant), one with acute renal failure and the other two
with multisystem failure probably owing to sepsis. Two of
these three patients were in complete remission before
transplant. There have been eight treatment-related deaths
in patients in remission (seven CR, one PR), one patient
developed fevers 3 months after transplant and died of
'septicaemia' in another hospital, no post-mortem was
obtained and this patient was classified as in continued
remission. One patient assessed as in PR after high-dose
treatment died of cryptococcus meningitis 8 months after
treatment; no evidence of HD was found at post-mortem.
The details of the six patients who died of lung toxicity will
be the subject of a separate publication.
There were two cases of leukaemia in the remission group
and as these patients were heavily pretreated this is not
considered a direct toxicity of the high-dose therapy. One
patient with progressive disease going into high-dose
treatment died of a protein-losing enteropathy 2.5 months
after treatment and unfortunately no post-mortem was
permitted. One patient with a background of a depressive
personality, in remission, committed suicide 4.5 years after
high-dose treatment. Thus the late toxic mortality rate overall
is 8/86=9%, or including the three early toxic deaths 11/
89 =12% and in the complete remission patients the late
toxic mortality rate was 7/55 = 13%.
Second malignancies (Table III)
There were three deaths from second malignancies: one acute
myeloid leukaemia, one myelodysplastic syndrome with
subsequent leukaemia, in two patients in remission at 4 and
6 years, and one high-grade non-Hodgkin's lymphoma at 3
years in a patient with active HD. A fourth patient, aged 38
years, died of active HD but had also developed a squamous
carcinoma of the oral mucosa.
Survival
All patients are included in the survival analysis. Survival
overall is shown in Figure 1 with a 5 year survival of 41%.
Progression-free survival (PFS) and time to progression
The median PFS overall is 17 months with 40% alive and
progression-free at 5 years (Figure 2). However, for those in
CR at the time of ABMT or afterwards the probability of
ic
E
E
E
E
4
1:
I
1
Co
2-
Ce
a)
a)
aL)
01)
c
0.
Co
.0
a.
._
,0
CL-
0 1 2 3 4 5 6 7
Time since high-dose treatment (years)
Figure 2 Overall progression-free survival (n =89).
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Figure 1 Overall survival (n= 89).
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Figure 3 Progression-free survival by response to chemotherapy
before high-dose treatment.
Table III Late toxic deaths
Outcome fol- In
lowing ABMT Total Deaths PD Active HDa remission
CR 55 (62%) 19 9 2b 8c
PR 15 12 7d 3e 2
NR 16 12 gg 3h
aplus other cause of death. bOne pneumonitis, one multifocal encephalopathy. cSix
pneumonitis, one infection: 'septicaemia', no post mortem, 'one leukaemia'; dOne squamous
cell cancer of the head and neck. eThree infections: fungal, TB, bronchopneumonia. fOne
infection: cryptococcus meningitis; one leukaemia. 90ne protein-losing enteropathy. hOne high-
grade NHI.
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remaining progression-free is 75% at 20 months and this is
maintained up to 5 years (Figure 3). Removing the patients
with first CR does not change this graph. The PR graph
plateaus after 42 months at 60% and the NR/PD graph
plateaus after 15 months at 33%. There is no significant
difference between the group of NR and PD (P=0.27).
Univariate analysis
A total of 21 factors were looked at in univariate analysis for
influence on progression-free survival and survival at 5 years.
Performance status at the time of ABMT was not always
documented and therefore the accuracy of a retrospective
assessment from the case notes was considered unacceptable.
The following showed no significant influence on PFS or
survival: gender, histology, age (,<25 or>25 years), stage at
ABMT, symptoms ever (A/B), symptoms at ABMT,
extranodal disease at ABMT, bulky disease at ABMT,
category at ABMT (first CR, second CR, primary
refractory, responding relapse, resistant relapse), CR ever,
number of CRs (< 1, > 1), previous radiotherapy, number of
previous chemotherapy regimens (<3, >3), total number of
courses of previous chemotherapies (>13, < 13), length of
longest remission (>2 years, <2 years), previous bleomycin,
ABMT conditioning regimen, dose of BCNU (,<400, >400),
albumin at ABMT in g dl-I (<35, >35). The outcome
following the most recent treatment before high-dose
treatment (with or without the three untested) was the most
significant factor for both progression-free survival (chi-
squared test=9.69, P<0.025, Figure 3) and overall survival
(P=0.02). Treatment/response history in two groups as
follows: <3 regimens or previous CR as one group or >3
regimens but never CR as a second group, was also
significant for progression-free survival and survival
(P=0.004 and P=0.01 respectively).
Table IV Multivariate analysis
Outcomefollowing most recent
chemotherapy before high-dose treatment Hazard ratio (for PFS)
CR I
PR 1.87
NR or progression 3.74
<3 regimens or previous CR 1
>3 regimens and no CR 3.19
Responding relapse 1.71
Primary refractory or resistant relapse 3.42
<3 Tx or CR ever (n = 76)
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Multivariate analysis (Table IV)
A Cox's multivariate analysis produced a model in which
response to the chemotherapy regimen before ABMT and
treatment/response history were the factors which predicted
long-term freedom from progression with this procedure
(Table IV, Figures 3 and 4). No other additional factor
improved the fit. Putting these two groups together produced
four Cox groups A-D (A, CR to most recent treatment; B,
PR to most recent treatment, CR previously or <3 regimens;
C, NR/PD to most recent treatment, CR previously or <3
regimens; D, never CR and >3 regimens) to give a predictive
model shown in Figure 5. This model divides the patient
population broadly into a group of 56/86 (65%) patients
(Cox group A+B, i.e. CR or PR to most recent treatment
and a CR previously or <3 previous treatment regimens)
with at least a 70% chance of being progression free from 1
year onwards and the other groups (Cox group C, D) with a
poorer prognosis (chi-square= 12.46, P<0.01). If response to
the last chemotherapy was excluded from the model, then the
category at ABMT (e.g. sensitive relapse etc.) produced a
model which was nearly as good as the model constructed
using sensitivity to the previous chemotherapy regimen
(Table IV, Figure 6).
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Figure 5 Progression-free survival by response to ABMT by Cox
group from multivariate analysis.
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Figure 4 Progression-free treatment/response to chemotherapy
proir to high-dose treatment. Figure 6 Progression-free survival using sensitivity classification.
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Table V Studies of high-dose chemotherapy in Hodgkin's disease
Median PFS overall (%) (CR %)
No. of Mortality CR rate follow-up- 24-36 48 60
patients (%) (%) months months months months
Carella et al. (1988) 50 7 48 24 45 45
Jagannath et al. (1989) 61 7 47 24 40 (77)
Phillips et al. (1989) 26 23 69 54 38 (39)
Jones et al. (1990) 28 21 64 26 51 (65)
Reece et al. (1991) 56 21 80 42 47
Gianni et al. (1993) 25 0* 72 67 48 (78)
Tourani et al. (1992) 39 10 79 48
Chopra et al. (1993) 155 10 34 24 50
Crump et al. (1993) 73 10 75 30 39 (68)
Goldstone and McMillan (1993) 947 29 34 37 35 (40)
Vose et al. (1992) 70 11 59 36 51 (22)
Yalahom et al. (1993) 47 17 74 40 52 (80) 50 50 (80)
Rapoport et al. (1993) 47 25 24 24 49 (70)
Anderson et al. (1993) 68 18
Bierman et al. (1993) 128 17 48 77 25
Royal Marsden Hospital, (1995) 89 22 67 43 48 (75) 45 41 (75)
Only includes studies with at least 24 patients and a median follow up of >24 months. * + GCSF; + PBSC.
Discussion
There have been two reports from this centre on the use of
high-dose treatment in Hodgkin's disease (Zulian et al., 1989;
Harding et al., 1992). For this analysis the database has been
updated and status of disease and response to previous
treatment and high-dose treatment verified by two physicians.
In addition, some patients in the earlier report were treated
with single-agent melphalan at suboptimal doses
(<140 mgm-2) and are now excluded. There are now 89
patients with a median follow-up of survivors of 43 months
(range 6-77 months), which means that this is one of the
larger series in the literature and meaningful interpretation
can be given to both the survival and progression-free
survival data and to the results of a multivariate analysis
on the prediction of response to this treatment.
For patients who achieved a CR before ABMT, the
plateau on the graph is at 75% with no late relapses. For PRs
before high-dose chemotherapy, the plateau occurs after 45
months and remains at 60%. There is also a plateau on the
graph for the group of NR/PD after 15 months and
remaining at 33%. At this point in our series we have three
cases of second malignancies that have resulted in death. Our
acute toxicities were due in most cases to lung disease which
can now be predicted and avoided in many cases by
reduction of the BCNU dose and the early use of steroids.
To date, the 'category' at ABMT as originally described
for non-Hodgkin's lymphoma, e.g. resistant relapses etc., has
been the gold standard for response assessment. This
categorisation does produce a model very similar to that
obtained using response to last chemotherapy but only when
response to last chemotherapy has been excluded from the
analysis (Figure 6). However, retrospective assessment of
response is difficult, with the possible exception of a CR. Our
prognostic model has been constructed using the hard end
points of previous treatment, namely the attainment of a CR
ever, the number of previous chemotherapy regimens and the
response to the chemotherapy before high-dose therapy.
Using this approach we have been able reliably to select the
group of patients for whom high-dose chemotherapy will be
most successful (hazard ratio= 1) and identify poor risk
cases. This prognostic index remains unproven but could
easily be applied to bone marrow transplantation registry
data.
Table V summarises the larger reported series of similar
patients treated with high-dose chemotherapy with a median
follow-up of at least 24 months and at least 25 patients in
each series. This is an attempt to compare our results with
other groups. Jones et al. (1990) reported their series of 50
patients which included 21 patients treated with an allograft
and found that a complete or partial remission at the time
of transplant was not a significant prognastic factor, but the
presence of sensitive disease at the time of transplantation
was a favourable prognostic sign for surviving event-free.
The efficacy of high-dose chemotherapy with bone marrow
rescue has been shown to be greater when there is some
degree of sensitivity to the therapy (Lohri et al., 1991;
Carella et al., 1988; Jagannath et al., 1989) Lohri et al.
(1991) also reported a very strong negative impact on
outcome in patients with stage IV disease at presentation,
recurrence within a year of primary treatment or presence of
B symptoms ar recurrence. We did not find any of these
factors to be significant in our study as most have been
employed to predict response to second line therapy whereas
most of our patients were at different stages in their disease,
usually much later when the duration of first response may
not have been relevant. In addition, like so many other
high-dose experiences, the group is made up of a number of
subtypes of disease and the paucity of numbers in each
group makes any interpretation meaningless; a meta-analysis
may help in the subgroup analysis.
This prognostic index should now be applied to a large
series of patients with Hodgkin's disease who have received
high-dose treatment.
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